|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Akt-induced endo- crine therapy resistance is reversed by inhibition of mTOR signaling显示文摘 | Beeram M Tan QT Tekmal RR | 2007 | Ann Oncol2007，18，8： | 1 |
| 2 | Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling显示文摘 | Beeram M Tan Q TN Tekmal R R | 2007 | Annals of Oncology2007，18，8： | 1 |
| 3 | Sequential optimization and reliabilityassessment for multidisciplinary systems design显示文摘 | Du X P Guo J Beeram H | 2008 | Struct Mul-tidisc Optim2008，35，： | 1 |
| 4 | Sequential optimization and reliability assessment for multidisciplinary systems design显示文摘 | Du X Guo J Beeram H | 2008 | Structural and Multidisciplinary Optimization2008，35，2： | 1 |
| 5 | Phase I study of trasmzum- ab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive meta static breast cancer显示文摘 | Krop IE Beeram M Modi S | 2010 | J Clin Oncol2010，28，16： | 1 |
| 6 | Positron emission tomography in the management of unknown primary head and neck carcinoma显示文摘 | Miller FR Hussey D Beeram M | 2005 | Arch Otolaryngol Head Neck Surg2005，131，7： | 1 |
| 7 | Sequential Optimization and Reliability Assessment for Multidisciplinary Systems Design 显示文摘 | Du X Guo J Beeram H | 2008 | Structure Multidisciplinary Optimization2008，35，： | 1 |
| 8 | A phase I and pharmacokinetic study of pemetrexed plus irinotecanin patients with advanced solid malignancies显示文摘 | ROWINSKY EK BEERAM M HAMMOND LA et d | 2007 | Clin Cancer Res2007，13，2： | 1 |
| 9 | A phase Iand pharma- cokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies显示文摘 | Rowinsky EK Beeram M Hammond LA | 2007 | Clin Cancer Res2007，13，21： | 1 |
| 10 | Phase I study of trastuzumab-DM1,a HER-2 antibody-drug conjugate,given every 3 weeks to patients with HER-2-positive metastatic breast cancer显示文摘 | Krop IE Beeram M Modi S | | 0，，16： | 1 |
| 11 | A phase 1 open-label, accelerated dose-escalation study of the hypoxia-actirated prodrug A QdN in patients with advanced malignancies显示文摘 | PAPADoPOuLos K P GOEL S BEERAM M | 2008 | Clin Cancer Res2008，14，21： | 1 |
| 12 | A phase I study of trastuzumab-DM1 (T-DM1),a first-in-class HER2 antibody-drug conjugate (ADC),in patients (pts) with advanced HER2+ breast cancer (BC)显示文摘 | Beeram M Burris HA Ⅲ Modi S | 2008 | J Clin Oncol2008，26，15： | 1 |
| 13 | Phase I study of trastuzu- mab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer 显示文摘 | Krop IE Beeram M Modi S | 2010 | J Clin Oncol2010，28，16： | 1 |
| 14 | PhaseⅧstudy of trastuzum-ab-DM1,an Her-2antibody-drug conjugate,given every3weeks to patients with Her-2-positive metastatic breast cancer显示文摘 | Krop IE Beeram N Modi S | 2010 | J Clin Oncol2010，28，16： | 1 |
| 15 | A phase I study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer显示文摘 | Beeram M Krop IE Burris HA | 2012 | Cancer2012，118，23： | 1 |
| 16 | Regulation of c-Raf-1:therapeutic implications显示文摘 | BEERAM M PATNAIK A ROWINSKY EK | 2003 | Clin Adv Hematol Oncol2003，1，8： | 1 |
| 17 | A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2- positive breast cancer显示文摘 | BEERAM M KROP I E BURRIS H A | 2012 | Cancer2012，118，23： | 1 |
| 18 | Phase I study of trastuzumab-DM1 ,an HER2 anti- body-drug conjugate,given every 3 weeks to patients with HER2-positive metastatic breast cancer 显示文摘 | Krop IE Beeram M Modi S | 2010 | J Clin Oncol2010，28，16： | 1 |
| 19 | Sequential optimization and reliability assessment for multidiseiplinary systems design 显示文摘 | DU Xiaoping GUO Jia BEERAM H | 2008 | Structural and Multidiseiplinary Optimization2008，35，2： | 1 |
| 20 | A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies 显示文摘 | Papadopoulos K P Goel S Beeram M | 2008 | Clin Cancer Res2008，14，21： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员